The evolving risk of sudden cardiac death after heart transplant. An analysis of the ISHLT Thoracic Transplant Registry

被引:17
|
作者
Alba, Ana C. [1 ]
Fan, Chun-Po S. [2 ]
Manlhiot, Cedric [2 ]
Dipchand, Anne I. [2 ]
Stehlik, Josef [3 ]
Ross, Heather J. [1 ]
机构
[1] Univ Hlth Network, Toronto Gen Hosp, Heart Failure & Transplantat Program, Toronto, ON, Canada
[2] Univ Toronto, Dept Paediat, Labatt Family Heart Ctr, Toronto, ON, Canada
[3] Univ Utah, Sch Med, Salt Lake City, UT USA
关键词
cardiac allograft vasculopathy; heart transplant; rejection; risk; sudden cardiac death; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; ALLOGRAFT VASCULOPATHY; NONISCHEMIC CARDIOMYOPATHY; INTERNATIONAL SOCIETY; PRIMARY PREVENTION; RECIPIENTS; MORTALITY; FAILURE; MODE;
D O I
10.1111/ctr.13490
中图分类号
R61 [外科手术学];
学科分类号
摘要
Sudden cardiac death (SCD) is responsible for similar to 10% of post-heart transplant deaths. We conducted a retrospective analysis of the ISHLT registry evaluating the risk of post-transplant SCD. Adult heart transplant recipients (2004-2014) surviving the first year were included. We used multivariable multistate competing risk survival analysis to evaluate the impact of history of treated rejection and cardiac allograft vasculopathy (CAV) on SCD risk. We used a probabilistic analytical model and Monte Carlo simulation to estimate the impact of CAV severity and graft dysfunction on SCD. We included 25 242 recipients. During a median follow-up of 4.7 (2.3-7.0) years, 582 patients died suddenly. Treated rejection (HR 1.76, 95% CI 1.36-2.31) and CAV (HR 3.32, 95% CI 2.73-4.03) were important risk factors for SCD. The estimated SCD risk in patients with severe CAV without and with graft dysfunction was 3.2% (95% CI 2.0-4.6) and 5.4% (95% CI 3.8-7.0), respectively, at 2 years from the CAV diagnosis, and 4.9% (95% CI 3.4-6.5) and 8.0% (95% CI 6.1-10.0), respectively, in those who also had treated rejection. These results provide evidence that recipients with severe CAV and graft dysfunction or treated rejection are at clinically significant increased SCD risk. The benefit of ICD post-transplant remains uncertain.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Donor thyroid hormone therapy and heart transplantation outcomes: ISHLT transplant registry analysis
    Peled, Yael
    Ram, Eilon
    Klempfner, Robert
    Lavee, Jacob
    Cherikh, Wida S.
    Stehlik, Josef
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (10): : 1070 - 1078
  • [22] Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: An analysis of the joint UNOS/ISHLT thoracic registry
    Hosenpud, JD
    Bennett, LE
    [J]. TRANSPLANTATION, 2001, 72 (10) : 1662 - 1665
  • [23] Clinical Outcomes Associated With mTORi Initiation in Adult Heart Transplant: An ISHLT Registry Analysis
    Posada, J. G. Duero
    Moayedi, Y.
    Alhussein, M.
    Bhagra, S.
    Fan, S.
    Manlhiot, C.
    Stehlik, J.
    Dipchand, A. I.
    Ross, H. J.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : S19 - S19
  • [24] RISK FACTORS FOR SPECIFIC CAUSES OF DEATH FOLLOWING PEDIATRIC HEART TRANSPLANT: AN ANALYSIS OF THE INTERNATIONAL SOCIETY OF HEART AND LUNG TRANSPLANT REGISTRY
    Vanderlaan, R.
    Manlhiot, C.
    McCrindle, B.
    Dipchand, A.
    Edwards, L.
    [J]. PEDIATRIC TRANSPLANTATION, 2015, 19 : 101 - 101
  • [25] Age Dependent Risk of LVAD Used as a Bridge to Transplant and of Comorbidities on Post-Transplant Survival: An Analysis of ISHLT Registry
    Masetti, M.
    Wilk, A. R.
    Grigioni, F.
    Russo, A.
    Edwards, L. B.
    Lund, L. H.
    Stehlik, J.
    Potena, L.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S31 - S32
  • [26] An aging population of patients with cystic fibrosis undergoes lung transplantation: An analysis of the ISHLT Thoracic Transplant Registry
    Benden, Christian
    Goldfarb, Samuel B.
    Stehlik, Josef
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (11): : 1162 - 1169
  • [27] Clinical Outcomes of Cardiac Transplant Recipients Ten Years After Transplant.
    Feitell, S.
    Pirlamarla, P.
    Kunnirickal, S.
    Brink, M.
    Whittier, J.
    Rowe, T.
    Hankins, S.
    Eisen, H.
    [J]. TRANSPLANTATION, 2014, 98 : 428 - 428
  • [28] Age Trends for Cystic Fibrosis Patients Undergoing Lung Transplantation: An Analysis of the ISHLT Thoracic Transplant Registry
    Benden, C.
    Edwards, L. B.
    Goldfarb, S. B.
    Yusen, R. D.
    Stehlik, I.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2016, 35 (04): : S70 - S71
  • [29] A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - An analysis of the national registry
    Jay, Colleen
    Ladner, Daniela
    Wang, Edward
    Lyuksemburg, Vadim
    Kang, Raymond
    Chang, Yaojen
    Feinglass, Joseph
    Holl, Jane L.
    Abecassis, Michael
    Skaro, Anton I.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 55 (04) : 808 - 813
  • [30] Ezetimibe for hypercholesterolemia in patients after heart transplant.
    Plesa, M
    Patel, JK
    Marquez, A
    Nakashima, J
    Kobashigawa, JA
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (01) : S145 - S145